Loading
A phase 3 trial of Cisplatin, Gemcitabine, Gemcitabine + cisplatin and Durvalumab in biliary tract cancer, run by Akeso, active and no longer recruiting.
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer is a phase 3 interventional study registered as NCT06591520 by Akeso, with 682 participants enrolled, started 2024-10-20 and due to reach its primary completion in 2026-10. Interventions recorded: AK112, Gemcitabine, Cisplatin and Durvalumab, Gemcitabine, Cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma), Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Shares Durvalumab, Gemcitabine, Platinum agents, Cisplatin and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
Shares Gemcitabine, Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/